CTL019 Out of Specification MAP for ALL or DLBCL Patients

NCT ID: NCT03601442

Last Updated: 2025-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release where no overwhelming safety concerns has been identified for manufacture and release of the out of specification product.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lymphoblastic Leukemia (ALL) Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTL019

CTL019

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

tisagenlecleucel Kymriah

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria:

1. Patients must be treated at a healthcare facility that has been certified /qualified by Novartis to dispense and administer tisagenlecleucel in line with the tisagenlecleucel Risk Evaluation and Mitigation Strategy (REMS) in the United States (US) or the local Risk Management Plan (RMP).

\- Note that tisagenlecleucel treatment should be initiated under the direction of and supervised by a HCP experienced in the treatment of hematological malignancies and trained for administration and management of patients treated with tisagenlecleucel. The healthcare facility must have tocilizumab for use in the event of cytokine release syndrome and emergency equipment per patient prior to infusion on site and ensure timely access to additional doses of tocilizumab; for detailed requirements refer to the approved local label.
2. Patients must be prescribed tisagenlecleucel in line with the locally approved indications (for the precise indication statements see approved local product label). These may include:

* pediatric and young adult patients up to and (including) 25 years of age with refractory/relapsed (r/r) acute lymphoblastic leukemia (B-ALL)
* adult patients with r/r diffuse large B-cell lymphoma (DLBCL)
3. Informed consent must be obtained prior to treatment
4. The incoming apheresis material and/or the final manufactured product is out of specification due to failure to meet acceptance or release specifications

Exclusion Criteria

Patients eligible for this Treatment Plan must not meet any of the following criteria:

1\. Contraindications as per the approved local label or the IB.
Minimum Eligible Age

1 Day

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Banner MDACC

Gilbert, Arizona, United States

Site Status AVAILABLE

University of Arizona Cancer Center

Phoenix, Arizona, United States

Site Status AVAILABLE

Banner University of Arizona Medical Center

Phoenix, Arizona, United States

Site Status AVAILABLE

Phoenix Children's Hospital

Phoenix, Arizona, United States

Site Status AVAILABLE

Phoenix Childrens Hospital

Phoenix, Arizona, United States

Site Status AVAILABLE

Banner Uni Medical Center Tucson

Tucson, Arizona, United States

Site Status AVAILABLE

City of Hope National Medical Center Hematology&HematCellTransplant

Duarte, California, United States

Site Status AVAILABLE

City of Hope

Duarte, California, United States

Site Status AVAILABLE

Children's Hospital Los Angeles CRFB002H2301

Los Angeles, California, United States

Site Status AVAILABLE

Children's Hospital Los Angeles

Los Angeles, California, United States

Site Status AVAILABLE

Childrens Hospital Los Angeles

Los Angeles, California, United States

Site Status AVAILABLE

Mattel Childrens Hospital UCLA

Los Angeles, California, United States

Site Status AVAILABLE

University of California at Los Angeles UCLA

Los Angeles, California, United States

Site Status AVAILABLE

Lucile Packard Children s Hospital Stanford University

Palo Alto, California, United States

Site Status AVAILABLE

Lucile Packard Childrens Hospital

Palo Alto, California, United States

Site Status AVAILABLE

Stanford University Medical Center

Palo Alto, California, United States

Site Status AVAILABLE

UC San Diego

San Diego, California, United States

Site Status AVAILABLE

University of California at San Diego, Moores Cancer Ctr UCSD

San Diego, California, United States

Site Status AVAILABLE

Rady Children s Hospital Dept of Oncology

San Diego, California, United States

Site Status AVAILABLE

Rady Childrens Hospital

San Diego, California, United States

Site Status AVAILABLE

Ucsf Benioff Childrens Hospital Pediatric Hematology Oncology

San Francisco, California, United States

Site Status AVAILABLE

University of Califronia San Francisco

San Francisco, California, United States

Site Status AVAILABLE

University of California, Los Angeles

Santa Monica, California, United States

Site Status AVAILABLE

Stanford Healthcare

Stanford, California, United States

Site Status AVAILABLE

Children's Hospital Colorado

Denver, Colorado, United States

Site Status AVAILABLE

Yale Cancer Center

New Haven, Connecticut, United States

Site Status AVAILABLE

University of Miami Hospital

Miami, Florida, United States

Site Status AVAILABLE

JHMI All Children s Hospital

St. Petersburg, Florida, United States

Site Status AVAILABLE

Emory University School of Medicine Emory University (12)

Atlanta, Georgia, United States

Site Status AVAILABLE

Emory University School of Medicine/Winship Cancer Institute Winship Cancer Center

Atlanta, Georgia, United States

Site Status AVAILABLE

Emory University School of Medicine/Winship Cancer Institute

Atlanta, Georgia, United States

Site Status AVAILABLE

Children's Healthcare of Atlanta Cellular Therapies Lab

Atlanta, Georgia, United States

Site Status AVAILABLE

Northside Hospital

Atlanta, Georgia, United States

Site Status AVAILABLE

Ann and Robert H Lurie Childrens Hospital of Chicago

Chicago, Illinois, United States

Site Status AVAILABLE

Northwestern

Chicago, Illinois, United States

Site Status AVAILABLE

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status AVAILABLE

University of CHicago Comer Children's Hospital Regulatory

Chicago, Illinois, United States

Site Status AVAILABLE

University of Chicago

Chicago, Illinois, United States

Site Status AVAILABLE

Healthwatch Plaza Research Associates

Louisville, Kentucky, United States

Site Status AVAILABLE

University of Maryland Medical Center UMMC

Baltimore, Maryland, United States

Site Status AVAILABLE

University of Maryland Medical Center

Baltimore, Maryland, United States

Site Status AVAILABLE

University of Maryland

Baltimore, Maryland, United States

Site Status AVAILABLE

Johns Hopkins Outpatient Center

Baltimore, Maryland, United States

Site Status AVAILABLE

Johns Hopkins University Hospital

Baltimore, Maryland, United States

Site Status AVAILABLE

Tufts Medical Center

Boston, Massachusetts, United States

Site Status AVAILABLE

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Site Status AVAILABLE

Massachusetts General Hospital DF/HCC institutions

Boston, Massachusetts, United States

Site Status AVAILABLE

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status AVAILABLE

MGH Cancer Center MGH Cancer Center

Boston, Massachusetts, United States

Site Status AVAILABLE

MGH Cancer Center

Boston, Massachusetts, United States

Site Status AVAILABLE

Dana Farber Cancer Institute Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status AVAILABLE

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Site Status AVAILABLE

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Site Status AVAILABLE

University of Michigan IRB

Ann Arbor, Michigan, United States

Site Status AVAILABLE

University of Michigan Medical Center

Ann Arbor, Michigan, United States

Site Status AVAILABLE

University of Michigan Health System

Ann Arbor, Michigan, United States

Site Status AVAILABLE

Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status AVAILABLE

Moffitt Cancer Center

Detroit, Michigan, United States

Site Status AVAILABLE

Wayne State University - Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status AVAILABLE

Henry Ford Hospital Henry Ford

Detroit, Michigan, United States

Site Status AVAILABLE

University of Minnesota Masonic Childrens Hospital

Minneapolis, Minnesota, United States

Site Status AVAILABLE

University of Minnesota

Minneapolis, Minnesota, United States

Site Status AVAILABLE

Mayo CLinic

Rochester, Minnesota, United States

Site Status AVAILABLE

WUSTL Jewish Barnes

St Louis, Missouri, United States

Site Status AVAILABLE

Hackensack University Medical Center Hackensack UMC

Hackensack, New Jersey, United States

Site Status AVAILABLE

Hackensack University Medical Center Onc Dept

Hackensack, New Jersey, United States

Site Status AVAILABLE

Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States

Site Status AVAILABLE

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Site Status AVAILABLE

Roswell Park Cancer Institute Rosewell

Buffalo, New York, United States

Site Status AVAILABLE

Roswell Park Cancer Institute

Buffalo, New York, United States

Site Status AVAILABLE

Memorial Sloan Kettering

New York, New York, United States

Site Status AVAILABLE

Memorial Sloan Kettering Cancer Center MSKCC

New York, New York, United States

Site Status AVAILABLE

Memorial Sloan Kettering Cancer Center Oncology

New York, New York, United States

Site Status AVAILABLE

Columbia University Medical Center New York Presbyterian CUMC Research Pharmacy

New York, New York, United States

Site Status AVAILABLE

Columbia University Medical Center New York Presbyterian Neuroendocrine Unit

New York, New York, United States

Site Status AVAILABLE

Memorial Sloan Kettering Cancer Center MSKCC (9)

New York, New York, United States

Site Status AVAILABLE

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status AVAILABLE

University of North Carolina Chapel Hill Physician Office Building

Chapel Hill, North Carolina, United States

Site Status AVAILABLE

University of North Carolina Health System

Chapel Hill, North Carolina, United States

Site Status AVAILABLE

Atrium Heath

Charlotte, North Carolina, United States

Site Status AVAILABLE

Duke University Medical Center Dept. of DUMC (4)

Durham, North Carolina, United States

Site Status AVAILABLE

Duke University Medical Center

Durham, North Carolina, United States

Site Status AVAILABLE

Cincinnati Children s Hospital Medical Center

Cincinnati, Ohio, United States

Site Status AVAILABLE

Cincinnati Childrens Hospital

Cincinnati, Ohio, United States

Site Status AVAILABLE

Oncology Hematology Care Inc Drug Shipment

Cincinnati, Ohio, United States

Site Status AVAILABLE

University Hospitals Cleveland Medical Center Univ. Hospitals of Cleveland

Cleveland, Ohio, United States

Site Status AVAILABLE

Nationwide Childrens Hospital Center

Columbus, Ohio, United States

Site Status AVAILABLE

OSU Wexner MC James CH

Columbus, Ohio, United States

Site Status AVAILABLE

The Ohio State University Hospitals Clinic The Ohio State University

Columbus, Ohio, United States

Site Status AVAILABLE

The Ohio State University Hospitals Clinic

Columbus, Ohio, United States

Site Status AVAILABLE

The Ohio State University Regulatory

Columbus, Ohio, United States

Site Status AVAILABLE

The Ohio State University Comprehensive Cancer Center Ohio State UMC James Cancer Ct

Columbus, Ohio, United States

Site Status AVAILABLE

Hematology Oncology Center, Inc.

Elyria, Ohio, United States

Site Status AVAILABLE

Oregon Health Sciences University

Portland, Oregon, United States

Site Status AVAILABLE

Oregon Health and Science University

Portland, Oregon, United States

Site Status AVAILABLE

OHSU

Portland, Oregon, United States

Site Status AVAILABLE

Oregon Health and Science University

Portland, Oregon, United States

Site Status AVAILABLE

Childrens Hospital of Philadelphia CTRB 3006

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Children's Hospital of Philadelphia Children's Hospital Of Phil(2)

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Children s Hospital of Philadelphia Patient Treatment

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Children s Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

The Childrens Hospital of Philadelphia Children's Hosp Philadelphia

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

The Childrens Hospital of Philadelphia Pediatric Oncology/Stem Cell T

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

The Childrens Hospital of Philadelphia Regulatory

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

University of Pennsylvania Health System CERL080AUS90

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Pennsylvania Oncology/Hemotology Dept.ofPenn. Onc./Hem.

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Site Status AVAILABLE

University of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania, United States

Site Status AVAILABLE

Medical University of South Carolina MUSC

Charleston, South Carolina, United States

Site Status AVAILABLE

Prisma Health Cancer Institute

Greenville, South Carolina, United States

Site Status AVAILABLE

Avera McKennan Hospital and University Health Center

Sioux Falls, South Dakota, United States

Site Status AVAILABLE

Methodist University Hospital Blood and Marrow Transplant

Memphis, Tennessee, United States

Site Status AVAILABLE

Texas Cancer Center ( Medical City Dallas Hospital) TX Cancer Center

Dallas, Texas, United States

Site Status AVAILABLE

Univof Texas Southwestern Medical Center, Dept of Pediatrics

Dallas, Texas, United States

Site Status AVAILABLE

U of TX Southwestern Medical Center - SimmonsCompCancerCtr Satellite

Dallas, Texas, United States

Site Status AVAILABLE

UT Southwestern Medical Center Pediatric Hematology/Onc

Dallas, Texas, United States

Site Status AVAILABLE

UT Southwestern Medical Center UT SW Medical Ctr of Dallas

Dallas, Texas, United States

Site Status AVAILABLE

Cook Children's

Fort Worth, Texas, United States

Site Status AVAILABLE

Texas Children's Hospital Baylor College of Medicine

Houston, Texas, United States

Site Status AVAILABLE

Baylor College of Medicine

Houston, Texas, United States

Site Status AVAILABLE

Houston Methodist Cancer Center Methodist Cancer Center (2)

Houston, Texas, United States

Site Status AVAILABLE

Houston Methodist Hospital

Houston, Texas, United States

Site Status AVAILABLE

MD Anderson Cancer Center/University of Texas MDACC

Houston, Texas, United States

Site Status AVAILABLE

MD Anderson Cancer Center/University of Texas StudyCoordinator:CTKI258A2102

Houston, Texas, United States

Site Status AVAILABLE

MD Anderson Cancer Center

Houston, Texas, United States

Site Status AVAILABLE

Methodist Hospital / Methodist Cancer Center Houston Methodist Hospital

Houston, Texas, United States

Site Status AVAILABLE

Methodist Healthcare System

San Antonio, Texas, United States

Site Status AVAILABLE

Methodist Hospital

San Antonio, Texas, United States

Site Status AVAILABLE

University of Utah / Huntsman Cancer Institute Huntsman Cancer Cente

Salt Lake City, Utah, United States

Site Status AVAILABLE

Primary Childrens Medical Center Oncology

Salt Lake City, Utah, United States

Site Status AVAILABLE

LDS Hospital

Salt Lake City, Utah, United States

Site Status AVAILABLE

University of Virginia Health Systems UVA

Charlottesville, Virginia, United States

Site Status AVAILABLE

VCU Health Systems, MCV

Richmond, Virginia, United States

Site Status AVAILABLE

Fred Hutchinson Cancer Research Center Dept. of FHCRC

Seattle, Washington, United States

Site Status AVAILABLE

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Site Status AVAILABLE

University of Wisconsin Hospital and Clinics Hematopoietic Stem Cell Lab

Madison, Wisconsin, United States

Site Status AVAILABLE

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Site Status AVAILABLE

University Wisconsin Children's Hospital

Madison, Wisconsin, United States

Site Status AVAILABLE

Childrens Hospital of Wisconsin

Milwaukee, Wisconsin, United States

Site Status AVAILABLE

Medical College of Wisconsin Med College of WI (29)

Milwaukee, Wisconsin, United States

Site Status AVAILABLE

Novartis Investigative Site

Murdoch, Western Australia, Australia

Site Status AVAILABLE

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status AVAILABLE

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status AVAILABLE

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs

Role: CONTACT

1-888-669-6682

Novartis Pharmaceuticals

Role: CONTACT

+41613241111

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

480-256-3333

Role: primary

602-406-8262

Role: primary

520-626-3576

Role: primary

602-546-0985

Role: primary

602-546-0895

Role: primary

626-930-5452

Role: primary

323-361-8552

Role: primary

323-660-2450

Role: primary

323-660-2450

Role: primary

310-206-2436

Role: primary

650-723-4000

Role: primary

650-736-0388

Role: primary

619-622-5731

Role: primary

858-822-5369

Role: primary

858-966-5118

Role: primary

858-966-7785

Role: primary

415-342-2762

Role: primary

415-353-2305

Role: primary

310-582-4069

Role: primary

203-200-4363

Role: primary

727-767-4150

Role: primary

404-778-2214

Role: primary

404-778-5747

Role: primary

404-785-1721

Role: primary

404-851-5926

Role: primary

312-227-4779

Role: primary

312-695-6737

Role: primary

312-355-1470

Role: primary

502-634-3090

Role: primary

410-328-8610

Role: primary

410-328-4394

Role: primary

410-955-6776

Role: primary

617-636-7462

Role: primary

617-726-5765

Role: primary

617-726-8743

Role: primary

617-726-8228

Role: primary

617-643-3715

Role: primary

617-724-0786

Role: primary

617-632-5607

Role: primary

617-632-4272

Role: primary

617-632-4295

Role: primary

734-936-5504

Role: primary

313-576-8994

Role: primary

313-576-8712

Role: primary

313-916-8862

Role: primary

612-624-9193

Role: primary

612-625-9125

Role: primary

507-284-2505

Role: primary

201-615-7251

Role: primary

551-996-8849

Role: primary

732-235-6031

Role: primary

716-845-4886

Role: primary

716-845-4485

Role: primary

646-227-2131

Role: primary

212-639-3859

Role: primary

646-317-4850

Role: primary

212-305-4921

Role: primary

646-888-0992

Role: primary

919-843-5497

Role: primary

919-668-1043

Role: primary

800-344-2462

Role: primary

513-636-0606

Role: primary

513-751-2273

Role: primary

216-844-7164

Role: primary

614-293-2887

Role: primary

614-366-0542

Role: primary

614-688-6563

Role: primary

440-324-0425

Role: primary

503-494-5431

Role: primary

503-494-5893

Role: primary

503-494-0896

Role: primary

503-418-2294

Role: primary

215-590-5476

Role: primary

215-662-6394

Role: primary

267-425-3010

Role: primary

267-426-9338

Role: primary

215-898-0208

Role: primary

215-590-9959

Role: primary

215-590-7399

Role: primary

267-426-7252

Role: primary

215-590-4029

Role: primary

215-615-0773

Role: primary

412-623-2393

Role: primary

214-648-1854

Role: primary

214-648-8594

Role: primary

214-456-6742

Elizabeth Gordon

Role: primary

Role: primary

832-822-4585

Role: primary

713-790-7850

Role: primary

832-470-8643

Role: primary

713-792-1046

Role: primary

210-575-3064

Role: primary

210-575-3817

Role: primary

801-581-6363

Role: primary

801-581-7715

Role: primary

434-243-8588

Role: primary

206-667-5836

Role: primary

608-265-6410

Role: primary

608-263-5003

Role: primary

608-263-4900

Role: primary

608-265-6020

Role: primary

414-805-4603

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCTL019B2003I

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of LYL314 in Aggressive Large B-Cell Lymphoma
NCT05826535 RECRUITING PHASE1/PHASE2
Retreatment With CTL019/CTL119
NCT04419909 NOT_YET_RECRUITING PHASE1
Treatment for Advanced B-Cell Lymphoma
NCT01859819 COMPLETED PHASE2
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489 RECRUITING PHASE2
Dynamic CtDNA-guided Targeted Therapy in DLBCL
NCT06748521 NOT_YET_RECRUITING PHASE2